Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites - Wikidata - wikimedia - TriplyDB

Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites

Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites

http://www.wikidata.org/entity/Q36153347

about

Antibody-based immunotherapy for ovarian cancer: where are we at?Antibody Therapies in Cancer.Clinical Pharmacology and Translational Aspects of Bispecific Antibodies Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives.Molecular biology of liver cancer stem cells.Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report.Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab.Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab.Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms.Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer.EpCAM and its potential role in tumor-initiating cells.Catumaxomab: in malignant ascites.Therapeutic application of monoclonal antibodies in cancer: advances and challenges.Monoclonal antibodies therapies for ovarian cancer.Clinical pharmacology of bispecific antibody constructs.A murine-human chimeric IgG antibody against vascular endothelial growth factor receptor 2 inhibits angiogenesis in vitro."NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies.Specific immunotherapy in ovarian cancer: a systematic review.Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells.Predominant expression of truncated EpCAM is associated with a more aggressive phenotype and predicts poor overall survival in colorectal cancer.The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.Prognostic impact of epithelial cell adhesion molecule in ovarian cancer patients.Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study.AZ17: a new bispecific drug targeting IL-6 and IL-23 with potential clinical use--improves psoriasis in a human xenograft transplantation model.Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary.Bispecific antibodies: design, therapy, perspectives.Transient human anti-mouse antibody generated with immune enhancement in a carbohydrate antigen 19-9 immunoassay after surgical resection of recurrent cancer.Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies.Bispecific antibodies in cancer immunotherapy Emerging classes of armed antibody therapeutics against cancer Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity ADME for Therapeutic Biologics: Antibody-Derived Proteins and Proteins with Novel Scaffolds

P2860

Q27000514-FFA08152-8A59-4871-8C1C-1AB7FD676675 Q31104000-2CC9B243-B5FD-4A3D-89F7-745FAC8DE78E Q33648086-1FEA4751-8126-46A4-812E-D41FB41DDC97 Q33755476-0E613B39-2966-4310-AC2C-A0373CECE577 Q33756006-BFF87CD1-DCB1-40E0-96FF-ECBC7203ED6C Q35079157-C06133FD-0BF0-4A3C-8A44-1BEB82F27CD1 Q35109585-B6A9207D-B228-423D-882D-FF29A2EA2688 Q36214720-77ED47D8-B915-47F1-88EA-28ACED86D633 Q36358324-BE238B60-EE1A-4DA1-AF4B-1C90DEB35E67 Q36413103-0EF102C3-E628-45A1-8FF9-005C75589A0F Q36478769-286EB5AD-D97C-4114-937D-2D4B256D6462 Q36797398-A4A513A4-18A2-4BAA-8ED7-3657A6944B4F Q37076922-05A1E874-6511-4973-AA72-A51787B936BA Q37225693-D68867F2-598A-4339-B323-27539B5C5C77 Q38014664-0DED066D-BD89-42B2-9696-BC79CB2C6D09 Q38016957-D27F935A-2804-475A-B638-7BBAABCA44D1 Q38057179-FE7DFEF7-F9E5-417C-B14A-AF4A2848B98A Q38078400-AEE38DC8-353B-42EF-B8F1-FB5E0DCCFDD2 Q38364459-B7CB76B1-6CAE-4A6C-AFDC-0F3B9E41BE4D Q38597921-D41D3A96-EF2A-4338-A542-4C844DBEC862 Q38723957-33C0F04F-CB91-4680-8E95-EEA6CDBB04D7 Q38790644-84B9936D-7DC1-4028-AF26-C33875C081B0 Q38948893-D6F714A6-9F96-4CF8-8452-0F7E373DED29 Q39323781-D5B312B0-B3B7-4782-814A-D96F5F74B6C3 Q40842917-157EDB61-CF98-4B3A-B7D3-31D9ED265C51 Q41279960-3DA6B54E-1D55-447C-9560-AF87E8AE1C58 Q42942406-26433BC8-CEDF-4A40-8336-E0C31E95B471 Q43728324-C3D99073-3DDE-4EBE-8692-DDE41C6D47EC Q45795416-3A6B4342-1A0B-4565-9877-05596F0F4B06 Q45849410-430C9D81-80F3-41C1-BF1E-AED056372D56 Q49195146-B16149AB-B3A8-4BCA-837F-F73FD2B54465 Q53216541-4F1F4D2E-879C-4E34-93F5-8EA9D598EFD5 Q53672090-0D8CDC4E-60DB-4FDA-A60C-70CC63D4D202 Q56893015-4364D32A-85C8-4CAB-819A-C8F8F8EFB7F7 Q57911948-CC75A1A5-C342-4462-9A7D-C405A8F7CA5C Q58722575-DD9486CC-E9E1-452F-B377-A605BE8157C8 Q58869554-F020A75E-2B1F-4520-8E2B-3F4439F6D11E

P2860

Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites

http://www.wikidata.org/entity/Q36153347

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Humoral response to catumaxoma ...... atients with malignant ascites

@ast

Humoral response to catumaxoma ...... atients with malignant ascites

@en

type

label

Humoral response to catumaxoma ...... atients with malignant ascites

@ast

Humoral response to catumaxoma ...... atients with malignant ascites

@en

prefLabel

Humoral response to catumaxoma ...... atients with malignant ascites

@ast

Humoral response to catumaxoma ...... atients with malignant ascites

@en

P1433

Q36153347-719E84F6-4B24-4714-9DA8-DCD69F6B0811

P1476

Q36153347-79BFC55B-1A41-4261-8F36-7E7494B6DC4E

P2093

Q36153347-596C8D2D-BC6D-4C44-A452-4E8341AFC8A1

Q36153347-631DFB76-BDB4-450A-A9FE-EBC3C9F91689

Q36153347-74EC3C74-EEC0-47E2-8E41-78E461932F52

Q36153347-7688BB6F-E200-40E9-BBBF-21F888F13540

Q36153347-A04987B1-2CEE-4502-9AA1-7D21B0C4F237

Q36153347-A655A65B-E0B8-493A-BD05-04741E8586F8

Q36153347-BD5C1C47-3847-4C9F-9747-0161154894F7

Q36153347-EBBBD100-95F9-48A2-8D4A-3CD7EF03680E

P2860

Q36153347-0D7C00B5-934A-4766-A954-9D3FCA8EA34B

Q36153347-0EB78261-5092-40AE-9AE7-0884CB3E33AA

Q36153347-100ED936-5376-4B2A-BDAB-8FF9EA26D9E2

Q36153347-17C7834E-57BB-40D7-A38E-FB020C70DEE1

Q36153347-20FF2843-0284-4C7E-8681-5DB5EB58AE4D

Q36153347-4D317716-F91D-48B3-9BDD-7E07F5199EB2

Q36153347-5AF36EEC-B6D3-4B58-9513-52BD629F8D29

Q36153347-5EA185D0-0007-444A-9AC1-E3AFC757FFFF

Q36153347-77DDCBB4-DCE2-4D11-A0C7-28E5128FE3F4

Q36153347-A2187C53-F7C6-485D-AA8C-5698303C3208

P304

Q36153347-E43F05ED-9A1A-4024-889A-7CB8EC4B1D3B

P31

Q36153347-58998780-2D02-49AF-8DCC-1B9380EF5637

P356

Q36153347-43571973-D4BA-4A42-9B4D-E556480A6DFE

P433

Q36153347-129598AE-03E2-4F3A-BC62-75F0E124752D

P478

Q36153347-CE3EFBF3-268D-4FAA-A0A0-59A8B57B142A

P50

Q36153347-30C9817A-F995-41C2-80AF-4AED782F1269

P577

Q36153347-F8202B97-C0FD-4BCA-A3C1-63D6AA10915E

P5875

Q36153347-70D68933-8E7F-4A61-84B4-6E66085A5A95

P698

Q36153347-6C0ECA43-D73D-4D1F-9E11-979D361FA6C4

P932

Q36153347-24D2C115-137B-44EF-9D2B-468E088112DF

P356

P1433

International Journal of Cancer

P1476

Humoral response to catumaxoma ...... atients with malignant ascites

@en

P2093

Diane Seimetz

http://www.w3.org/2001/XMLSchema#string

Frederik Marmé

http://www.w3.org/2001/XMLSchema#string

Gerhard Moldenhauer

http://www.w3.org/2001/XMLSchema#string

Horst Lindhofer

http://www.w3.org/2001/XMLSchema#string

Marion G Ott

http://www.w3.org/2001/XMLSchema#string

Mirko M Essing

http://www.w3.org/2001/XMLSchema#string

Rolf Linke

http://www.w3.org/2001/XMLSchema#string

Rolf Spannagl

http://www.w3.org/2001/XMLSchema#string

P2860

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

Have we overestimated the benefit of human(ized) antibodies?

Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies.

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.

Human antiglobulin response to foreign antibodies: therapeutic benefit?

A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words.

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis.

Monoclonal antibodies for cancer immunotherapy.

P304

2195-2203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.26258

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51246796

http://www.w3.org/2001/XMLSchema#string

P698

21702044

http://www.w3.org/2001/XMLSchema#string

P932

3415680

http://www.w3.org/2001/XMLSchema#string